NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
WORX
SCWorx Corp.
There isn't enough reported data to score WORX yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
WORX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
WORX's revenue is currently stable, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
WORX PE Valuation
WORX has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
WORX Forward outlook
There aren't enough analyst estimates for WORX to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the stronger earnings trend. Trailing diluted EPS is up 4.9% for NVO versus WORX down 131%.
WORX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$174.60 | +$397.80 |
| Q2 2025 | -$196.20 | +$462.60 |
| Q1 2025 | -$160.20 | +$478.80 |
| Q4 2024 | -$140.40 | +$554.40 |
| Q3 2024 | -$572.40 | -$302.40 |
| Q2 2024 | -$658.80 | -$442.80 |
| Q1 2024 | -$639.00 | -$315.00 |
| Q4 2023 | -$694.80 | -$289.80 |
WORX is still losing money, but far less than before: $174.60 per share over the past year, against $972.00 at its worst in late 2021.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over WORX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over WORX on profitability, with a higher operating margin.
WORX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $706K | +3.4% |
| Q1 2026 | $744.9K | +3.4% |
| Q4 2025 | $768.9K | +14% |
| Q3 2025 | $705.8K | -7.1% |
| Q2 2025 | $682.6K | -8% |
| Q1 2025 | $720.3K | -11% |
| Q4 2024 | $675.7K | -26% |
| Q3 2024 | $759.7K | -16% |
WORX's revenue fell from its 2019 peak and has held roughly level since: $706,049 last quarter, up 3.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -17% | +26 points |
| Q1 2026 | -18% | +28 points |
| Q4 2025 | -25% | +31 points |
| Q3 2025 | -20% | +32 points |
| Q2 2025 | -43% | -1.6 points |
| Q1 2025 | -46% | -24 points |
| Q4 2024 | -56% | -51 points |
| Q3 2024 | -52% | +43 points |
WORX's operating margin was −17% last quarter, up 26 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the stronger cash trend. Its trailing FCF is down 14% versus its history, compared with WORX at down 25%.
WORX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$5.7K | +$646.1K |
| Q1 2026 | -$252.7K | +$151.9K |
| Q3 2025 | -$358.1K | +$4.5K |
| Q2 2025 | -$651.8K | -$124.1K |
| Q1 2025 | -$404.6K | -$345.1K |
| Q4 2024 | -$134.4K | -$29.6K |
| Q3 2024 | -$362.6K | +$10.2K |
| Q2 2024 | -$527.8K | -$180K |
WORX has burned cash in almost every quarter: −$1M over the past year, against −$1M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over WORX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
WORX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +852 shares |
| 1 year | +735% | +78.6K shares |
| 3 years | +1897% | +84.8K shares |
| 5 years | +2406% | +85.7K shares |
WORX has 89,269 diluted shares, up 735% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
WORX Net Leverage
WORX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
WORX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.5 | Neutral |
| Stochastic | 4.1 | Oversold |
WORX's weekly RSI is 36 (neutral) and its Stochastic is 4 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
WORX PE vs Healthcare Sector
WORX has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over WORX on trend strength, trading above more of its moving averages.
WORX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.39 | 47% below |
| 20 week MA | $4.13 | 69% below |
| 50 week MA | $19.4 | 93% below |
| 100 week MA | $80.5 | 98% below |
| 200 week MA | $313.5 | 100% below |
WORX is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over WORX on returns for 2026, with the stronger performance.
WORX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7,722.0 | $4,104.0 | -47% |
| 2021 | $4,104.0 | $3,699.0 | -9.9% |
| 2022 | $3,699.0 | $1,107.0 | -70% |
| 2023 | $1,107.0 | $331.2 | -70% |
| 2024 | $331.2 | $302.4 | -8.7% |
| 2025 | $302.4 | $37.8 | -88% |
| 2026 YTD | $37.8 | $1.27 | -97% |
WORX has finished every year since 2020 lower, and it's down 97% so far in 2026.